Abstract:Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity. Here we have studied various ways to model ex vivo T cell function in order to compare the impact of the clinically utilised anti-PD-1 antibody, pembrolizumab (Keytruda) on the activation of human T cells: focussing on the release of pro-inflammatory IFNγ and anti-inflammatory IL-10 to assess functionality. Firstly, we investigated the actions of pembrolizumab in an acute model of T-cell activation with either immature or mature allogeneic dendritic cells (DCs); pembrolizumab enhanced IFNγ and IL-10 release from purified CD4+ T-cells in the majority of donors with a bias towards pro-inflammatory cytokine release. Next, we modelled the impact of pembrolizumab in settings of more chronic T-cell activation. In a 7-day antigen-specific response to EBV peptides, the presence of pembrolizumab resulted in a relatively modest increase in both IFNγ and IL-10 release. Where pembrolizumab was assessed against long-term stimulated CD4+ cells that had up-regulated the exhaustion markers TIM-3 and PD-1, there was a highly effective enhancement of the otherwise exhausted response to allogeneic DCs with respect to IFNγ production. By contrast, the restoration of IL-10 production was considerably more limited. Finally, to assess a direct clinical relevance we investigated the consequence of PD-1/PD-L1 blockade in the disease setting of dissociated cells from lung and colon carcinomas responding to allogeneic DCs: here, pembrolizumab once more enhanced IFNγ production from the majority of tumour preparations whereas, again, the increase in IL-10 release was modest at best. In conclusion, we have shown that the contribution of PD-1-revealed by using a canonical blocking antibody to interrupt its interaction with PD-L1-to the production of an exemplar pro- and anti-inflammatory cytokine, respectively, depends in magnitude and ratio on the particular stimulation setting and activation status of the target T cell. We have identified a number of in vitro assays with response profiles that mimic features of dissociated cell populations from primary tumours thereby indicating these represent disease-relevant functional assays for the screening of immune checkpoint inhibitors in current and future development. Such in vitro assays may also support patient stratification of those likely to respond to immuno-oncology therapies in the wider population.

Reinvigorated exhausted T cells exhibit distinct features within 24 hours after PD-1 therapy

Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer

Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control

PD-1 immune checkpoint blockade can synergize with PSGL-1 inhibition to reinvigorate exhausted T cells

Precursor exhausted T cells: key to successful immunotherapy?

No more LAGging behind PD-1: uncovering the unique role of LAG-3 in T-cell exhaustion

Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade

PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Reprogramming of exhausted T cells following elimination of chronic antigen exposure

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

CD8 T-cell heterogeneity during T-cell exhaustion and PD-1-targeted immunotherapy

Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation

Exhausted T cells and epigenetic status

Antitumor progenitor exhausted CD8 + T cells are sustained by TCR engagement

The Primordial Differentiation of Tumor-Specific Memory CD8+ T Cells As Bona Fide Responders to PD-1/PD-L1 Blockade in Draining Lymph Nodes.

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion